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ABSTRACT
Objective: This study aimed to get the genotypic and allelic frequencies of rs1801282 in 179 volunteer 
donors and 154 patients with Metabolic syndrome (MetS) in Brasilia, Brazil and also examine the 
association with anthropometric, biochemical and hemodynamic variables in the latter group. MetS 
comprises a group of diseases resulting from insulin resistance, in-creased risk of type 2 diabetes and 
atherosclerotic cardiovascular disease. MetS is defined by the presence of increased visceral fat, ath-
erogenic dyslipidemia (elevated triglycerides (TGL)), with decreased high density lipoprotein (HDL) 
and increased low density lipoprotein (LDL) levels, hypertension (BPH) and disturbances in glucose 
homeostasis representing a significant burden across the world due to the alarming increase in the 
incidence over the last decades besides their significant morbidity and mortality. Peroxisome prolifer-
ator activated receptor-gamma (PPARg) has been mentioned as a candidate gene for determining the 
risk of MetS. It is a member of the nuclear receptors superfamily and a ligand-activated transcription 
factor, which regulates the expression of genes involved in the network lipogenesis and adipogen-
esis, insulin sensitivity, energy balance, inflammation, angiogenesis and atherosclerosis. Among the 
PPARG genetic variants, single nucleotide polymorphism rs1801282 has been the most extensively 
studied one since it was first described by Yen and cols. in 1997. This polymorphism is characterized 
by the replacement of a proline (CCC) to an alanine (GCA) at codon 12 of exon B, due to the exchange 
of a cytosine with a guanine. The Ala allele frequency varies in different ethnic groups. Materials and 
methods: DNA was extracted using Chelex-100 method and determinations of genotypes were per-
formed by allele-specific chain reaction. Results: The distribution of genotype frequency of the MetS 
group was not statistically different from the frequency in the donor population at large. In the first 
group, genotype frequency was CC to 0.869 and 0.103 for CG, while allelic frequencies were 0.948 for 
C and 0.052 for G allele. In the group of donors, the genotype and allele frequencies were 0.882 for 
CC, 0.117 to CG; and 0.941 to 0.059 for G and C, respectively. GG genotype was not found in any of the 
two groups. The genotype distribution and allele frequencies were in Hardy-Weinberg equilibrium. 
No marker could be detected from the analysis of anthropometric, biochemical and hemodynamic 
variables in the MetS group. Conclusion: Our data suggest that this polymorphism is not correlated 
with predisposition to MetS. The results obtained on a small sample of the population of Brasilia, 
corroborate the data reported in the literature on the prevalence of this polymorphism in PPAR in 
populations of different ethnic origins. Arch Endocrinol Metab. 2015;59(4):297-302
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M etabolic syndrome (MetS) comprises a group of related disorders stemming from insulin resis­
tance and leading increased risk of type 2 diabetes and 
atherosclerotic cardiovascular disease. MetS is defined 
by the presence of increased visceral adiposity, athe­
rogenic dyslipidemia [increased triglycerides (TGL), 
with decreased high­density lipoprotein (HDL), and 
increased low­density lipoprotein (LDL) cholesterol 
serum levels], hypertension (HBP), and disturbances 
in glucose homeostasis (1). It represents a significant 
worldwide burden due to the alarming increase in its 
incidence over the last decades, in addition to its sig­
nificant morbidity and mortality (2).
Environmental and life­style changes are widely ac­
cepted as the key factors driving insulin resistance (3) 
and adiposity (4) and hence the current epidemics of 
MetS. However, they don’t fully explain its occurrence 
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role in determining the predisposition to the syndrome. 
PPARG is a plausible candidate gene in determining 
the risk of MetS. It encodes peroxisome proliferator­ac­
tivated receptor gamma (PPARg), a member of the nu­
clear hormone receptor superfamily of ligand­activated 
transcription factor, which regulates the expression of 
network of genes involved in adipogenesis and lipoge­
nesis, insulin sensitivity, energy balance, inflammation, 
angiogenesis and atherosclerosis (5).
Among the genetic variants of PPARG, the 
rs1801282 single nucleotide polymorphism has been 
the most extensively studied one since its first descrip­
tion by Yen and cols. in 1997 (6). This variant is char­
acterized by the replacement of a proline (CCA) by 
an alanine (GCA) at codon 12 of exon B, due to the 
exchange of a cytosine for a guanine. The Ala allele 
frequency ranges from 2 to 23% in different ethnic 
groups (7). Its frequency is low in Asian and African 
populations (1 to 3%) (6) and higher in Caucasians 
(20%) (8­10). Deeb and cols. (11) were among the 
first researches to describe the functional implications 
of the Alla allele, by demonstrating that this variant 
displayed decreased binding affinity to the cognate 
promoter element and reduced ability to transactivate 
PPARg-responsive promoters. These findings sug­
gested that the rs1801282 variant could contribute 
to the observed lower body mass index (BMI) and 
insulin sensitivity among the carriers of this polymor­
phism (11).
However, subsequent studies in different popula­
tions have proposed opposed conclusions. Some de­
scribe that the presence of polymorphisms confers a 
protective effect with respective do type 2 diabetes risk 
(12), whereas others indicate that it is associated with 
increased susceptibility to the disease (8,13). There 
are also studies in which no association was found be­
tween this variant and the frequency of type 2 diabetes 
(14­16). To our knowledge, the association between 
the PPARG variant rs1801282 and the risk of meta­
bolic diseases has not been addressed in the Brazilian 
population. The aim of the present study was there­
fore to describe the genotypic and allelic frequency of 
the rs1801282 polymorphism among MetS patients 
from the University Hospital of Brasilia, in compari­
son with control subjects from Brasilia, Brazil. We also 
investigated whether the biochemical and anthropo­
metric variables differed among MetS patients with the 
PPARG Ala variant when compared to those with the 
wild type Pro/Pro genotype.
MATERIALS AND METHODS
Subjects
All 154 MetS subjects enrolled in this study were 
from the population treated at the University Hospi­
tal of Brasilia. The patients were unrelated, aged over 
45 years and had MetS in accordance to the National 
Cholesterol Education Program/Adult Treatment 
Panel III (NCEP/ATPIII) criteria (17). The 179 un­
related volunteers, of both sexes, aged over 45, were 
blood donors from Blood Center Foundation of Brasil­
ia. It was not possible to assess this population  in all 
anthropometric and biochemical variables  defined by 
NCEP ATPIII for MetS. However, the selection cri­
teria helped us to exclude patients with diabetes (gly­
cated hemoglobin < 6.5%) (18), hypertension (BP < 
130/85 mmHg) (19) and obesity (BMI < 30) (20). In 
both groups, the exclusion criteria were: patients who 
refused to participate in the study, under the age of 45 
years and using hyperglycemic medications such as glu­
cocorticoids. Written informed consent was obtained 
from each participant after a full explanation of the 
study, which was approved by the Ethics Committee 
of the Health Sciences School from the University of 
Brasilia. Written informed consent was obtained from 
each participant after a full explanation of the study, 
which was approved by the Ethics Committee of the 
Health Sciences School from the University of Brasilia.
Anthropometric measurements and blood chemistry
Height, weight, waist circumference (WC), systolic and 
diastolic blood pressures were measured and the results 
were averaged. The body mass index (BMI) was cal­
culated by dividing the weight (kg) by the height (m) 
squared. After an overnight fast, with at least 12 hours, 
blood samples were taken for determination of labo­
ratory parameters considered for this project: fasting 
glucose, total cholesterol and fractions, triglycerides. 
All samples from patients with MetS were analyzed 
by conventional methods only in the Clinical Labora­
tory of the University Hospital of Brasilia. The results 
of biochemical tests were analyzed according to cutoff 
points proposed by the NCEP/ATPIII criteria used for 
classification of MetS.
rs1801282 genotyping 
A venous blood sample (5 mL) was obtained from 
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and EDTA­containing tubes. Samples from MetS 
patients were collected at the University Hospital of 
Brasilia and, from volunteers, at Hemocentro Brasilia 
Foundation. DNA was extracted by the Chelex­100 
method (21), and rs1801282 genotype assignments 
were conducted by allele­specific polymerase chain 
reaction. 
Initially, each pair of primers for the rs1801282 poly­
morphism was used in PCR reactions with allele specific 
singleplex, in a final volume of 25 µl containing 50 ng 
template DNA; 1 ng of each primer (direct, general and 
reverse); Syber Green Rox qPCR Master Mix Thermo 
Scientific and 1x H2O Milli­Q qs (primers under re­
quest). 
Amplifications were carried out in Step One Plus 
(Life Technologies®), which was composed of the fol­
lowing: denaturation at 95°C for 10 minutes; followed 
by 40 cycles of 15 seconds denaturation at 95°C, 1 
minute at 60°C and melting curve 95°C for 15 sec­
onds; 60°C 1 min, 95°C for 15 seconds.
Statistical analysis 
The categorical data were described as mean ± standard 
deviation. Variables were analyzed using nonparamet­
ric analysis (Mann Whitney test and Fisher). Hardy­
Weinberg equilibrium, differences in genotype and al­
lele frequencies between MetS and general individuals 
were analyzed by using Pearson’s c2 test in GenAlex 
Program. All statistical tests were carried out using 
GraphPad Prism version 6.00 for Windows, GraphPad 
Software, San Diego, California, USA (www.graphpad.
com). A p value < 0.05 was considered statistically sig­
nificant (two­tailed).
RESULTS
Genotyping was carried out for 333 unrelated subjects 
(154 MetS patients and 179 individuals from general 
population) from the University Hospital of Brasilia 
and from the Hemocentro Foundation of Brasilia, 
Brazil. In the MetS group, the mean age was 57.9 ± 
6.83 years and 67.53% were female. In the population 
group, the mean age was 49.33 ± 4.22 years, however 
the majority was male (67%). Clinical characteristics of 
the individuals enrolled in the study are presented in 
tables 1 and 2. 
The genotyping results are summarized in table 3. 
Deviation from the Hardy­Weinberg equilibrium was 
not seen in either the MetS (c2 = 0.462, df = 1, p = 
0.49) or the general group (c2 = 0.695, df = 1, p = 
0.404). The genotype distribution of the rs1801282 
polymorphism for the MetS was 0.896 for the CC gen­
otype and 0.103 for the CG genotype. For the general 
group, they were 0.888 and 0.112, respectively. There 
were no GG genotypes in both groups. The biochemi­
cal and anthropometric results for all MetS subjects 
are shown in table 4. No differences were seen in the 
mean values of age, height, weight, WC, BMI, plasma 
triglyceride, plasma total cholesterol, HDL and LDL 
cholesterol, as well as systolic and diastolic blood pres­
sure among different genotypes, when we analyzed the 
MetS group individually (Table 5). 
Table 1. Baseline characteristics of the metabolic syndrome subjects, 
University Hospital of Brasilia
n (154) Mean ± Standard deviation
Gender (M/F) 50/104
Age (years) 57.9 ± 6.83
Weight (kg) 79.87 ± 16.29
Height (cm) 1.62 ± 0.09
Waist circumference 111.61 ± 16.24
Systolic BP (mmHg) 131.50 ± 14.76
Diastolic BP (mmHg) 84.09 ± 7.97
BMI (kg/m2) 30.73 ± 6.57
FBS (mg/dL) 152.81 ± 73.66
Total-c (mg/dL) 184.89 ± 39.04
TGL (mg/dL) 180.92 ± 87.91
HDL-c (mg/dL) 42.25 ± 22.39
LDL-c (mg/dL) 108.67 ± 36.20
BP: blood pressure; BMI: body mass index; Total-c: total cholesterol; TGL: triglycerides; HDL-c: 
high density lipoprotein; LDL-c: low density lipoprotein; FBS: fasting glucose.
Table 2. Baseline characteristics of the volunteers subjects from the 
Hemocentro Foundation of Brasilia
n (179) Mean ± Standard deviation
Gender (M/F) 118/61
Age (years) 49.33 ± 4.22
Weight (kg) 77 ± 16.5
Height (cm) 1.72 ± 0.09
Systolic BP (mmHg) 124 ± 10.99
Diastolic BP (mmHg) 82 ± 10.83
BMI (kg/m2) 26.45 ± 4.32
Hb A1C (%) < 6.5%*
BP: blood pressure; BMI: body mass index; Total-c: total cholesterol; TGL: triglycerides; HDL-c: 
high density lipoprotein; LDL-c: low density lipoprotein; Hb A1C: glycated hemoglobin. 
* Criteria defined by the American Association of Diabetes and used by Hemocentro Foundation 
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DISCUSSION
The observational of individual differences in the risk 
of developing MetS has led to an increased interest in 
genetic factors that might determine the susceptibility 
to insulin resistance, since it is the core physiopatho­
logical component of MetS (22­24). The identification 
of candidate genes for the syndrome has therefore been 
a major focus of research over the last decades, and it 
is expected that these findings will translate into bet­
ter understanding of the physiopathology of MetS in 
addition to enabling the development of appropriate 
therapeutic and preventative strategies.
The initial description of the PPARG rs1801282 poly­
morphism in patients with type 2 diabetes across diverse 
populations placed the gene as an attractive candidate in 
studies addressing genetic factors associated with meta­
bolic disturbances. This was reinforced by well estab­
lished role of PPARg  in regulating key aspects of energy 
balance, including adipocyte differenciation, lipogenesis 
and insulin action, in addition to the inflammatory re­
sponse, angiogenesis and atherosclerosis (5). Many stud­
ies have subsequently investigated the association be­
tween rs1801282 and the various individual components 
of MetS. Nevertheless, few of them have explored this 
association with the MetS as an entity. Our study is one 
of the few studies investigating this association, and is the 
first one addressing this issue in a Brazilian population.
The distribution of rs1801282 polymorphism is quite 
wide, ranging from 0.630 to 0.956 for the CC genotype, 
from 0.015 to 0.300 for the CG genotype and from 0 to 
0.067 for GG. The frequency of the C allele ranges from 
0.780 to 0.977 and that of the G allele varies from 0.023 
to 0.220 for the G allele in an Iranian population (25). 
In the present study, we found that the frequency of the 
C allele was 0.95 and the frequency of the G allele was 
0.05 in both the MetS group and the non­MetS group, 
and these results are in line with previous results observed 
in the general population. Indeed, our findings are close 
to the data from other previously published studies inves­
tigating diverse populations, such as the Chinese (26), 
Italian (27), French (28), African American (29), Korean 






C (Pro) G (Ala) CC (Pro/Pro) CG (Pro/Ala) GG (Ala/Ala)
MetS 146 (94.8%) 5.2 (8%) 138 (89.61%) 16 (10.38%) 0
General population 168 (94.1%) 5.9 (11%) 159 (88.82%) 20 (11.17%) 0
MetS: metabolic syndrome.
Table 4. Comparison of biochemical, anthropometric and hemodynamic 









Gender (M/F) 46/92 04/12 0.3658
Age (years) 57.9 ± 6.87 58.12 ± 6.69 0.9238
FBG (mg/dL) 155.91 ± 76.59 126.31 ± 30.83 0.1562
Total-c (mg/dL) 183.71 ± 39.26 188.18 ± 47.66 0.4851
TGL (mg/dL) 184.22 ± 90.16 152.87 ± 60.84 0.2626
HDL-c (mg/dL) 42.45 ± 23.44 40.56 ± 9.95 0.4963
LDL-c (mg/dL) 107.49 ± 35.08 118.18 ± 44.40 0.3384
BMI (kg/m2) 30.94 ± 6.63 28.89 ± 5.28 0.2780
Waist circumference 111.93 ± 16.14 108.81 ± 17.37 0.4368
Systolic BP (mmHg) 131.67 ± 15.11 130 ± 11.54 0.8509
Diastolic BP (mmHg) 84.13 ± 8.17 83.75 ± 6.19 0.7248
BP: blood pressure; BMI: body mass index; Total-c: total cholesterol; TGL: triglycerides; HDL-c: 
high density lipoprotein; LDL-c: low density lipoprotein; FBG: fasting blood glucose.
Table 5. Association of rs1801282 genotypes and the presence of 
metabolic syndrome components
MetS components Pro12Pro n (%) CC
Pro12Ala n 
(%) CG p
FBS ≥ 100 (mg/dL) 133 (96.37%) 14 (87.5%) 0.1562
BP ≥ 130/85 mmHg 81 (58.69%) 7 (43.75%) 0.2925
TGL ≥ 150 mg/dL) 77 (55.79%) 8 (50%) 0.7919
HDL-c < 40 mg/dL (men) 24 (17.39%) 3 (18.75%) 0.1147
HDL-c < 50 mg/dL (women) 77 (55.79%) 8 (50%) 0.2251
WC ≥ 88 cm (women) 89 (64.49%) 11 (68.75%) 0.3923
WC ≥ 102 cm (men) 29 (21.01%) 3 (18.75%) 0.6292
MetS: metabolic syndrome; BP: blood pressure; BMI: body mass index; Total-c: total cholesterol; 
TGL: triglycerides; HDL-c: high density lipoprotein; LDL-c: low density lipoprotein; FBS: fasting 
glucose; WC: waist circumference.
The analysis of the frequencies of the individual com­
ponents of MetS also showed no significant difference 
among the genotypes (Table 6). To see if the effects 
of the polymorphisms were associated with hyperten­
sion (BP > 130/85 mmHg), obese (BMI > 30 kg/m2) 
or impaired fasting glucose (fasting glucose > 100 mg/
dL), we divided the MetS group in three subgroups, 
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(15), Scotish (30), German (31), Finn (28) and Hispanic 
(32) populations. Additionally, in the first five popula­
tions listed above, the Ala12Ala genotype was not found, 
reinforcing the rarity of this variant worldwide.
Similar to other studies, the association between 
the rs1801282 polymorphism and MetS risk was not 
found in this small sample from Brasilia population. 
Moreover, this variant was not associated with any of 
the investigated biochemical, anthropometric or hemo­
dynamic variables among the MetS group. A French 
population­based study involving 1,155 individuals, 
including 279 men and women with MetS defined ac­
cording to NCEP/ATPIII, concluded that none of 
the polymorphisms studied, including rs1801282, was 
associated with MetS risk (8). A small study involving 
253 Korean women diagnosed with MetS (also defined 
by NCEP/ATPIII recommendations) did not find any 
association of this syndrome with the genotypes ana­
lyzed. There were also no differences between BMI, 
blood pressure, fasting glucose levels, fasting insulin 
levels and insulin resistance defined by the homeostatic 
model assessment in Ala carriers when compared with 
dominant Pro allele (15).
Rooki and cols. investigated the association between 
two PPARG genotypes polymorphisms (rs3856806 and 
rs1801282) and their haplotypes in patients with MetS 
in 340 individuals from Iran (175 patients with MetS 
and 165 healthy controls), and found a significant dif­
ference between the frequency of rs3856806 frequencies 
among individuals with MetS and healthy controls, al­
though no association was found between the frequen­
cy of rs1801282 and the occurrence of MetS (33). Yang 
Table 6. Comparison of biochemical, anthropometric and hemodynamic variables data of metabolic syndrome subjects between different groups of 
rs1801282 genotypes in three subdivided groups according to hypertension, diabetes and obesity
MetS 
components
All subjects with MetS
Subjects with MetS  
and hypertension  
(BP ≥ 130/85 mm hg)
Subjects with MetS and diabetes
(FBS ≥ 100 mg/dL)
Subjects with MetS and obesity 
(BMI ≥ 30 kg/m2)
PRO12PRO
CC (N = 138) 
PRO12ALA
CG (N = 16)
PRO12PRO
CC (N = 81) 
PRO12ALA
CG (N = 7)
PRO12PRO
CC (N = 133) 
PRO12ALA
CG (N = 14)
PRO12PRO
CC (N = 69) 
PRO12ALA
CG (N = 7)
Systolic BP 
(mmHg)
131.67 ± 15.11 130 ± 11.54 140.72 ± 12.68 140 ± 8.16 131.66 ± 15.28 130.71 ± 12.06 132.59 ± 14.36 125.71 ± 9.75
Diastolic BP 
(mmHg)
84.13 ± 8.17 83.75 ± 6.19 87.29 ± 6.90 90 ± 0 83.99 ± 8.25 84.28 ± 6.46 84.21 ± 7.16 82.85 ± 4.87
FBS (mg/dL) 155.91 ± 76.59 126.31 ± 30.83 158.02 ± 87.87 127.85 ± 29.57 158.35 ± 76.97 131.64 ± 29.15 143.17 ± 49.01 131.71 ± 40.43
TGL (mg/dL) 184.22 ± 90.16 152.87 ± 60.84 191.27 ± 88.11 174.42 ± 63.80 185.54 ± 90.72 163.44 ± 57.46 177.44 ± 87.63 139.14 ± 47.92
HDL-c (mg/dL) 42.45 ± 23.44 40.56 ± 9.95 43.20 ± 28.66 38.71 ± 8.55 42.66 ± 23.82 39.28 ± 10.01 39.73 ± 11.14 42.14 ± 7.71
Waist 
circumference
111.93 ± 16.14 108.81 ± 17.37 112.50 ± 15.53 105.71 ± 17.19 111.56 ± 15.61 107.28 ± 15.10 119.72 ± 14.56 123.71 ± 14.04
MetS: metabolic syndrome; HDL-c: high density lipoprotein; BP: blood pressure; BMI: body mass index; TGL: triglycerides. 
P-value and the values  given refer to the crude analysis (i.e, not adjusted for age and sex).
and cols. also investigated the rs3856806 and rs1801282 
polymorphisms in 423 Chinese individuals with MetS 
and found that only rs3856 concluded that only the first 
one was associated with MetS (34). Another Chinese 
study with 792 subject from Beijing analyzed the cor­
relations between the occurrence of insulin resistance 
and MetS and the PPARG variants rs1801282 and 
rs3856806, and found both polymorphisms were associ­
ated with insulin results, but not with the components 
of MetS (35). Finally, results from a recent meta­anal­
ysis indicated that the rs1801282 polymorphism might 
not be related to MetS as an entity, but could affect 
the risk of the individual components of this syndrome 
(14). In our study, there was no association between the 
frequency of the rs1801282 polymorphism and either 
MetS as an entity or its individual components. 
In conclusion, the rs1801282 polymorphism in 
PPARG does not seem to be involved with MetS risk in 
a Brazilian population. We emphasize that a limitation 
of our study is the relatively small sample size. Thus, 
further studies with larger population bases are needed 
to clarify this issue.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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